Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis, Chit1
Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients
Title: Duplication in Chitotriosidase (CHIT1) Gene and the Risk for Aspergillus Lung Disease in CF Patients. Aim: To evaluate the link between CHIT1 duplication in CF patients and the predisposition to ABPA or persistent…
- Trial name
- NCT01572870
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rambam Health Care Campus
Staphylococcus Aureus Pneumonia, Lung Diseases
Mucoid Staphylococcus Aureus in Cystic Fibrosis Airways
Recently, the investigators described a new mucoid phenotype of Staphylococcus aureus cultured from the airways of cystic fibrosis (CF) patients.In this observational study, the investigators plan to determine the prevalence of…
- Conditions
- Staphylococcus Aureus Pneumonia, Lung Diseases, Cystic Fibrosis, Lung Function Decreased
- Trial name
- mucostaph (NCT04171583)
- Where
- 13 sites in Austria, Germany
- Volunteers
- 628 people
- Sponsor
- University Hospital Muenster
Cystic Fibrosis, Parenthood Status
Health Outcomes of Parents With Cystic Fibrosis-Aim 2
The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators.
- Trial name
- HOPeCF (NCT06296394)
- Testing
- Parenthood
- Where
- 18 sites in United States
- Volunteers
- 146 people
- Sponsor
- University of Pittsburgh
Cystic Fibrosis
Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF
CF is caused by mutations in the gene that encodes the 'Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)' channel. To re-establish the function of this complex chloride channel, typically two to three drug modes of…
- Trial name
- CHOICES (NCT06468527)
- Testing
- Diponecaftor
- Where
- 16 sites in Belgium, France and 7 more
- Volunteers
- 41 people
- Sponsor
- Kors van der Ent
Cystic Fibrosis
A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
To evaluate the efficacy of ivacaftor treatment, as measured by lung clearance index (LCI), in subjects with cystic fibrosis (CF) who have a specified CF transmembrane conductance regulator (CFTR) gating mutation
- Trial name
- NCT02742519
- Testing
- ivacaftor
- Where
- 6 sites in Australia, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
A major factor in the respiratory health of cystic fibrosis (CF) patients is acquisition of chronic Pseudomonas (P.) aeruginosa infections. The infection rate with P.
- Trial name
- NCT03905642
- Testing
- Arikayce™
- Where
- 11 sites in Belgium, Hungary and 5 more
- Volunteers
- 49 people
- Sponsor
- Insmed Incorporated
Cystic Fibrosis, Respiratory Viral Infection
Impact of Respiratory Viral Infections in Infants With Cystic Fibrosis.
Respiratory Viral Infections (RVI) are particularly frequent in young children. Old data mention the deleterious role of some viruses such as the Respiratory Syncytial Virus in young children with cystic fibrosis (CF).
- Trial name
- PREVIMUC (NCT02847156)
- Testing
- Physical assessment
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis
ANNE Sensor Monitoring in Cystic Fibrosis
The ANNE sensor is a small, wire free device that is placed on the chest with a removable adhesive patch. It measures things like temperature, heart rate and breathing rate without the need for wires and large machines that are…
- Trial name
- ASM in CF (NCT05941832)
- Testing
- ANNE Chest Sensor
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis
Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)
Patients with Cystic Fibrosis have increased oxidative stress and impaired antioxidant systems. Under certain conditions, docosahexaenoic acid (DHA) intake may have a favorable role in reducing redox status.
- Trial name
- OMEGAMUCO (NCT02690857)
- Testing
- Docosahexaenoic acid, Sunflower Oil
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
Osteoporosis, Muscular Dystrophy
Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
By supplying an adequate amount of calcium and vitamin D with the addition of weekly bisphosphonate, the investigators will be able to increase bone mass and decrease the incidence of fragility fractures in these children with…
- Conditions
- Osteoporosis, Muscular Dystrophy, Cystic Fibrosis
- Trial name
- NCT01882400
- Testing
- Bisphosphonate treatment
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Gilles Boire
Cystic Fibrosis (CF), Primary Ciliary Dyskinesia (PCD)
Exercise Capacity, Muscle Oxygenation, Respiratory Muscle Strength, and Physical Activity Level in Pediatric CF and PCD
Cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) are genetic diseases characterized by chronic respiratory tract infections.
- Trial name
- NCT07157644
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Gazi University
Cystic Fibrosis
Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
The purpose of this study is to determine whether AeroVanc treatment is safe and effective in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.
- Trial name
- NCT01746095
- Testing
- Vancomycin hydrochloride inhalation powder
- Where
- 38 sites in United States
- Volunteers
- 87 people
- Sponsor
- Savara Inc.
Cystic Fibrosis
VX-770 Expanded Access Program
The purpose of this expanded access program is to provide VX-770 prior to its commercial availability to people with cystic fibrosis (CF) who have at least one copy of the G551D-CFTR mutation and who are in critical medical need…
- Trial name
- NCT01381289
- Testing
- VX-770
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).
- Trial name
- BEGIN (NCT04509050)
- Testing
- Ivacaftor or elexacaftor/tezacaftor/ivacaftor
- Where
- 35 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sonya Heltshe
Cystic Fibrosis
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Cystic Fibrosis (CF) and if so how it compares to placebo (a substance which does not have any action).
- Trial name
- INCA (NCT00757848)
- Testing
- AZD9668
- Where
- 14 sites in Denmark, Germany and 4 more
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Cystic Fibrosis, Endothelial Dysfunction
Vascular Health and Function in Cystic Fibrosis
The goal of this observational study is to learn whether blood vessel health and function differ between adults aged 40 years or older with cystic fibrosis (CF) who are taking CFTR modulator therapy and healthy adults of the same…
- Conditions
- Cystic Fibrosis, Endothelial Dysfunction, Cardiovascular Risk Factor
- Trial name
- CF-VHF (NCT07904325)
- Testing
- Non-invasive vascular, cerebrovascular and autonomic assessment
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Idiopathic Granulomatous Mastitis, Granulomatous Mastitis
GRAnulomatous MAstitis REGistry Study
Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory breast condition with unknown cause, affecting approximately 2.4 per 100,000 women aged 20-40 years.
- Trial name
- GRAMAREG (NCT07422870)
- Where
- 2 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- European Breast Cancer Research Association of Surgical Trialists
Cystic Fibrosis
The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults
Respiratory viruses, such as those that cause colds and influenza, are very common in the general population. The average adult will experience between 2 and 4 viral respiratory illnesses each year.
- Trial name
- NCT01238081
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Manchester University NHS Foundation Trust
Cystic Fibrosis
The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis
The purpose of this randomized, placebo-controlled (Phase II) study will be to further evaluate the effects of oral glutathione on growth in children with CF.
- Trial name
- GROW (NCT03020719)
- Testing
- Oral Glutathione
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Minnesota
Cystic Fibrosis
Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients
Suppression of stop mutations in the CFTR gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the CFTR-mediated chloride transport in nasal and sweat…
- Trial name
- NCT00376428
- Testing
- Gentamicin
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.